Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 3
Submit an article Journal homepage
336
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

Soun Khounthama Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
Polina Shindiapinaa Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
Xiaokui Mob Center for Biostatistics, The Ohio State University, Columbus, OH, USAView further author information
,
Curtis Lachowiezc Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USAView further author information
,
Tracy Wiczerd Department of Pharmacy, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
Luay Mousaa Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
Kerry A. Rogersa Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
Leslie A. Andritsosa Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAORCID Iconhttps://orcid.org/0000-0003-0222-1766View further author information
ORCID Icon,
Jennifer A. Woyacha Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
John C. Byrda Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAView further author information
,
Stephen E. Spurgeonc Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USAView further author information
&
Farrukh T. Awane Division of Hematology and Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1813-9812View further author information
ORCID Icon show all
Pages 716-721 | Received 15 Apr 2020, Accepted 08 Oct 2020, Published online: 19 Nov 2020

References

  • Awan FT, Al-Sawaf O, Fischer K, et al. current perspectives on therapy for chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1–10.
  • Iskierka-Jażdżewska E, Puła B, Szeremet A, et al. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: a report from the Polish Adult Leukemia Study Group (PALG). Adv Clin Exp Med. 2019;28(8):1051–1057.
  • Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–2067.
  • Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–87.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
  • Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
  • Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
  • Mato AR, Lamanna N, Ujjani CS, et al. Toxicities and outcomes of ibrutinib-treated patients in the United States: large retrospective analysis of 621 real world patients. Blood. 2016;128(22):3222.
  • Mato AR, Roeker LE, Allan JN, et al. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018;93(11):1394–1401.
  • Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–1748.
  • Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9):1553–1562.
  • Thompson PA, Levy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–466.
  • Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood. 2016;128(22):638.
  • Jones J, Mato A, Coutre S, et al. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol. 2018;182(4):504–512.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.